{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:29:58Z","timestamp":1787048998081,"version":"build-2736575974"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The application of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors represents a crucial milestone in the field of lipid-lowering therapy. As the first PCSK9 inhibitor to be approved globally, evolocumab has not only offered an entirely novel therapeutic option for patients with familial hypercholesterolemia but also established a paradigm for the development of subsequent anti-PCSK9 monoclonal antibodies. This narrative review provides an overview of the discovery of PCSK9 and its role in low-density lipoprotein cholesterol metabolism, detailing the developmental trajectory and key clinical trials of evolocumab, and underscoring its central importance and transformative impact on lipid-lowering therapeutics. On this basis, we conduct a comparative analysis of the differences in mechanism of action, clinical efficacy and safety among the marketed PCSK9 inhibitors, and dissect the limitations and unmet needs in current clinical practice. Furthermore, this review explores the pleiotropic effects of PCSK9 beyond lipid metabolism, and comments on its potential application value and latest research advances in diseases such as infection, liver disease, and malignancy. Finally, we prospect the future development directions of PCSK9-targeted therapy, aiming to provide an integrated reference perspective for basic research and clinical practice in this field.<\/jats:p>","DOI":"10.3389\/fphar.2026.1800502","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T05:45:04Z","timestamp":1779342304000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A narrative review of PCSK9 inhibitors: from evolocumab to novel discoveries"],"prefix":"10.3389","volume":"17","author":[{"given":"Hui-Hui","family":"Liu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Heart Failure Center, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Cardiometabolic Center, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Cardiometabolic Center, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"B2","volume-title":"Label for Yixining\u00ae (Ebronucimab Injection)","year":"2024"},{"key":"B3","volume-title":"Label for REPATHA\u00ae (Evolocumab Injection for Subcutaneous Use)","year":"2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0192850","DOI":"10.1371\/journal.pone.0192850","article-title":"Malaria severity: possible influence of the E670G PCSK9 polymorphism: a preliminary case-control study in Malian children","volume":"13","author":"Arama","year":"2018","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"738764","DOI":"10.3389\/fcvm.2021.738764","article-title":"PCSK9\/LDLR system and rheumatoid arthritis-related atherosclerosis","volume":"8","author":"Arida","year":"2021","journal-title":"Front. Cardiovasc Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1097\/ms9.0000000000001601","article-title":"Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review","volume":"86","author":"Arsh","year":"2024","journal-title":"Ann. Med. Surg. (Lond)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/s0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside","volume":"9","author":"Bao","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.3390\/ijms22115880","article-title":"PCSK9 biology and its role in atherothrombosis","volume":"22","author":"Barale","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"105155","DOI":"10.1016\/j.neubiorev.2023.105155","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in the central nervous system","volume":"149","author":"Bell","year":"2023","journal-title":"Neurosci. Biobehav Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.jacc.2023.08.019","article-title":"Concomitant coronary atheroma regression and stabilization in response to lipid-lowering therapy","volume":"82","author":"Biccir\u00e8","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1161\/01.ATV.0000120374.59826.1b","article-title":"Brain cholesterol: long secret life behind a barrier","volume":"24","author":"Bj\u00f6rkhem","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000442976","article-title":"Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis","volume":"8","author":"Boyd","year":"2016","journal-title":"J. Innate Immun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.cell.2009.01.035","article-title":"Origins and mechanisms of miRNAs and siRNAs","volume":"136","author":"Carthew","year":"2009","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.Cd-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"B18","doi-asserted-by":"publisher","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","article-title":"PCSK9 inhibitors: a new era of lipid lowering therapy","volume":"9","author":"Chaudhary","year":"2017","journal-title":"World J. Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"965","DOI":"10.5114\/aoms.2017.69326","article-title":"Lipid lowering nutraceuticals in clinical practice: position paper from an international lipid expert panel","volume":"13","author":"Cicero","year":"2017","journal-title":"Arch. Med. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"108812","DOI":"10.1016\/j.pharmthera.2025.108812","article-title":"Therapeutic PCSK9 targeting: inside versus outside the hepatocyte?","volume":"268","author":"Corsini","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3233\/jad-170993","article-title":"PCSK9 concentrations in cerebrospinal fluid are not specifically increased in alzheimer's disease","volume":"62","author":"Courtemanche","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins","volume":"60","author":"Dias","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1515\/bc.2009.035","article-title":"Central nervous system: cholesterol turnover, brain development and neurodegeneration","volume":"390","author":"Dietschy","year":"2009","journal-title":"Biol. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1097\/SHK.0000000000000682","article-title":"Differential expression of PCSK9 modulates infection, inflammation, and coagulation in a murine model of sepsis","volume":"46","author":"Dwivedi","year":"2016","journal-title":"Shock"},{"key":"B27","unstructured":"Repatha (evolocumab): summary of product characteristics\n          \n          \n          2015"},{"key":"B28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.21037\/atm.2018.11.04","article-title":"Elevation of serum proprotein convertase subtilisin\/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus","volume":"6","author":"Fang","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"101614","DOI":"10.1016\/j.xcrm.2024.101614","article-title":"Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia","volume":"5","author":"Fang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"9340480","DOI":"10.1155\/2020\/9340480","article-title":"Association of the rs562556 PCSK9 gene polymorphism with reduced mortality in severe malaria among Malian children","volume":"2020","author":"Fedoryak","year":"2020","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.athplu.2024.11.003","article-title":"Emerging oral therapeutic strategies for inhibiting PCSK9","volume":"59","author":"Ferri","year":"2025","journal-title":"Atheroscler. Plus"},{"key":"B32","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ptr.6282","article-title":"Metabolic effect of berberine-silymarin association: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials","volume":"33","author":"Fogacci","year":"2019","journal-title":"Phytother. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13075-020-02386-7","article-title":"Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-\u03b1: potential underlying mechanisms","volume":"23","author":"Frosteg\u00e5rd","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/circulationaha.122.063399","article-title":"Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE","volume":"147","author":"Gaba","year":"2023","journal-title":"Circulation"},{"key":"B35","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1007\/s11427-023-2688-8","article-title":"Increase of PCSK9 expression in diabetes promotes VEGFR2 ubiquitination to inhibit endothelial function and skin wound healing","volume":"67","author":"Gao","year":"2024","journal-title":"Sci. China Life Sci."},{"key":"B37","first-page":"187","article-title":"Therapeutic siRNA: principles, challenges, and strategies","volume":"85","author":"Gavrilov","year":"2012","journal-title":"Yale J. Biol. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ebiom.2018.11.032","article-title":"Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors","volume":"38","author":"Genga","year":"2018","journal-title":"EBioMedicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00204-023-03492-6","article-title":"Understanding the molecular mechanisms of statin pleiotropic effects","volume":"97","author":"German","year":"2023","journal-title":"Arch. Toxicol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/vaccines11010002","article-title":"A cVLP-Based vaccine displaying full-length PCSK9 elicits a higher reduction in plasma PCSK9 than similar peptide-based cVLP vaccines","volume":"11","author":"Goks\u00f8yr","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/jcm10081621","article-title":"Rapid decline of serum proprotein convertase subtilisin\/kexin 9 (PCSK9) in non-cirrhotic patients with chronic hepatitis C infection receiving direct-acting antiviral therapy","volume":"10","author":"Grimm","year":"2021","journal-title":"J. Clin. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jacl.2019.10.015","article-title":"ODYSSEY EAST: alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand","volume":"14","author":"Han","year":"2020","journal-title":"J. Clin. Lipidol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"155505","DOI":"10.1016\/j.phymed.2024.155505","article-title":"A promising therapy for fatty liver disease: PCSK9 inhibitors","volume":"128","author":"Han","year":"2024","journal-title":"Phytomedicine"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/eurheartj\/eht528","article-title":"HIV infection and cardiovascular disease","volume":"35","author":"Hemkens","year":"2014","journal-title":"Eur. Heart J."},{"key":"B45","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/13543784.2024.2369747","article-title":"VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol","volume":"33","author":"Hooper","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B46","doi-asserted-by":"publisher","first-page":"100907","DOI":"10.1016\/j.lanwpc.2023.100907","article-title":"Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial","volume":"41","author":"Huo","year":"2023","journal-title":"Lancet Reg. Health West Pac"},{"key":"B47","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3892\/br.2019.1189","article-title":"Changes in serum LDL, PCSK9 and microRNA-122 in patients with chronic HCV infection receiving daclatasvir\/asunaprevir","volume":"10","author":"Ichikawa","year":"2019","journal-title":"Biomed. Rep."},{"key":"B48","volume-title":"Label for Tolesi\u00ae (Tafolecimab Injection)","year":"2024"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e70061","DOI":"10.1111\/cts.70061","article-title":"Clinical pharmacokinetics and pharmacodynamics of ongericimab: a potential long-acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: randomized, double-blind, placebo-controlled phase Ia and Ib\/II studies","volume":"17","author":"Jiang","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"B50","volume-title":"Label for Aixinan\u00ae (Recaticimab Injection)","year":"2025"},{"key":"B51","volume-title":"Label for Junmaikang\u00ae (Ongericimab for Injection)","year":"2024"},{"key":"B52","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"B53","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2147\/cpaa.S288831","article-title":"Safety and tolerability of PCSK9 inhibitors: current insights","volume":"12","author":"Kosmas","year":"2020","journal-title":"Clin. Pharmacol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3390\/jcm9040910","article-title":"Methotrexate decreases the level of PCSK9-A novel indicator of the risk of proatherogenic lipid profile in psoriasis. The preliminary data","volume":"9","author":"Krahel","year":"2020","journal-title":"J. Clin. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa2511778","article-title":"Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3","volume":"393","author":"Laffin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1172\/jci29383","article-title":"Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice","volume":"116","author":"Lagace","year":"2006","journal-title":"J. Clin. Invest"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e009996","DOI":"10.1161\/jaha.118.009996","article-title":"Coronary endothelial dysfunction is associated with elevated serum PCSK9 levels in people with HIV independent of low-density lipoprotein cholesterol","volume":"7","author":"Leucker","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1190934","DOI":"10.3389\/fphar.2023.1190934","article-title":"Chinese guideline for lipid management","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.biopha.2018.05.024","article-title":"Role of PCSK9 in lipid metabolism and atherosclerosis","volume":"104","author":"Lin","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1161\/142.suppl_3.12579","article-title":"Abstract 12579: CVI-LM001, a first-in-class novel oral PCSK9 modulator, lowers plasma Ldl-c and reduces circulating PCSK9 in preclinical animal models and in hyperlipidemic human subjects","volume":"142","author":"Liu","year":"","journal-title":"Circulation"},{"key":"B61","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/pharmaceutics17091102","article-title":"Nanodelivery of bioactive natural products: a targeted therapeutic breakthrough for atherosclerosis","volume":"17","author":"Liu","year":"2025","journal-title":"Pharmaceutics"},{"key":"B63","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jid.2018.07.046","article-title":"Potentiation of psoriasis-like inflammation by PCSK9","volume":"139","author":"Luan","year":"2019","journal-title":"J. Invest Dermatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/cir.0000000000001303","article-title":"2025 heart disease and stroke statistics: a report of US and global data from the American heart association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"B66","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B67","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00018-022-04237-x","article-title":"PCSK9 acts as a key regulator of A\u03b2 clearance across the blood-brain barrier","volume":"79","author":"Mazura","year":"2022","journal-title":"Cell Mol. Life Sci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ng0297-146","article-title":"Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice","volume":"15","author":"Mendez","year":"1997","journal-title":"Nat. Genet."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1007\/s11845-023-03323-8","article-title":"Circulating PCSK9 relates to aggravated disease activity, Th17\/Treg imbalance, and predicts treatment outcome of conventional synthetic DMARDs in rheumatoid arthritis patients","volume":"192","author":"Meng","year":"2023","journal-title":"Ir. J. Med. Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3390\/v15071511","article-title":"Plasma proprotein convertase subtilisin\/kexin type 9 (PCSK9) as a possible biomarker for severe COVID-19","volume":"15","author":"Mester","year":"2023","journal-title":"Viruses"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1007\/s10753-023-01821-6","article-title":"Circulating proprotein convertase subtilisin\/kexin type 9 (PCSK9) is associated with disease activity and risk of incident cardiovascular disease in patients with systemic lupus erythematosus","volume":"46","author":"Mok","year":"2023","journal-title":"Inflammation"},{"key":"B72","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jhep.2006.09.024","article-title":"The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus","volume":"46","author":"Molina","year":"2007","journal-title":"J. Hepatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.drudis.2017.01.006","article-title":"PCSK9 and diabetes: is there a link?","volume":"22","author":"Momtazi","year":"2017","journal-title":"Drug Discov. Today"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/17512433.2022.2132229","article-title":"The role of PCSK9 in NAFLD\/NASH and therapeutic implications of PCSK9 inhibition","volume":"15","author":"Momtazi-Borojeni","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4103\/jpdtsm.jpdtsm_112_2","article-title":"A systematic review with network meta-analysis on atherosclerosis vaccine based on nonhuman primate model","volume":"4","author":"Muzaffar","year":"2025","journal-title":"J. Prev. Diagnostic Treat. Strategies Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jacc.2022.10.030","article-title":"PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection","volume":"81","author":"Navarese","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the glagov randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"Jama"},{"key":"B78","volume-title":"Label for Leqvio\u00ae (Inclisiran Sodium Injection for Subcutaneous Use)","year":""},{"key":"B79","unstructured":"A randomized study to evaluate the effect of an \u201cinclisiran first\u201d implementation strategy compared to usual care in patients with atherosclerotic cardiovascular disease and elevated LDL-C despite receiving maximally tolerated statin therapy (victorion-initiate) (v-initiate)"},{"key":"B80","unstructured":"A randomized, double-blind, placebo -controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants established cardiovascular disease (victorion-2 prevent)"},{"key":"B81","unstructured":"A study of inclisiran to prevent cardiovascular events in high-risk primary prevention patients"},{"key":"B82","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.str.2007.04.004","article-title":"The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol","volume":"15","author":"Piper","year":"2007","journal-title":"Structure"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e023328","DOI":"10.1161\/jaha.121.023328","article-title":"Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis","volume":"11","author":"Punch","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity Statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"Jama"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/s2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1099\/vir.0.81749-0","article-title":"Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus","volume":"87","author":"Ren","year":"2006","journal-title":"J. Gen. Virol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ahj.2025.08.001","article-title":"Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow-limiting lesions identified in an in-hospital screening: the victorion-plaque primary prevention trial","volume":"291","author":"Revaiah","year":"2026","journal-title":"Am. Heart J."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"Jama"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"","journal-title":"N. Engl. J. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/s2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"101726","DOI":"10.1016\/j.xcrm.2024.101726","article-title":"Transforming hypercholesterolemia management: spotlight on PCSK9 peptide vaccines","volume":"5","author":"Sahebkar","year":"2024","journal-title":"Cell Rep. Med."},{"key":"B93","volume-title":"Label for Praluent\u00ae (Alirocumab Injection for Subcutaneous Use)","year":"2025"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa2019910","article-title":"Evolocumab in pediatric heterozygous familial hypercholesterolemia","volume":"383","author":"Santos","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/s2213-8587(16)30396-5","article-title":"PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study","volume":"5","author":"Schmidt","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1210\/endrev\/bnab035","article-title":"The multifaceted biology of PCSK9","volume":"43","author":"Seidah","year":"2022","journal-title":"Endocr. Rev."},{"key":"B98","doi-asserted-by":"publisher","first-page":"120408","DOI":"10.1016\/j.atherosclerosis.2025.120408","article-title":"Efficacy and safety of ongericimab in Chinese statin-intolerant patients with primary hypercholesterolemia or mixed dyslipidemia: a randomized, placebo-controlled phase 3 trial","volume":"407","author":"Shao","year":"2025","journal-title":"Atherosclerosis"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jacc.2024.09.012","article-title":"Recaticimab as Add-On therapy to statins for nonfamilial hypercholesterolemia: the randomized, phase 3 REMAIN-2 trial","volume":"84","author":"Sun","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11883-023-01186-z","volume":"26","author":"Surma","year":"2024","journal-title":"Curr. Atheroscler. Rep."},{"key":"B101","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40119-023-00304-x","article-title":"Efficacy and safety of evolocumab in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia: 12-week primary results of the HUA TUO randomized clinical trial","volume":"12","author":"Tan","year":"2023","journal-title":"Cardiol. Ther."},{"key":"B102","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11883-025-01299-7","article-title":"Oral PCSK9 inhibitors: will they work?","volume":"27","author":"Tokg\u00f6zo\u011flu","year":"2025","journal-title":"Curr. Atheroscler. Rep."},{"key":"B103","doi-asserted-by":"publisher","first-page":"ehaf784.1807","DOI":"10.1093\/eurheartj\/ehaf784.1807","article-title":"Intensified hypolipidaemic therapy with inclisiran for atherosclerotic plaque stabilization","volume":"46","author":"Trusinskis","year":"2025","journal-title":"Eur. Heart J."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e050675","DOI":"10.1136\/bmjopen-2021-050675","article-title":"Statin associated adverse reactions in Latin America: a scoping review","volume":"11","author":"Urina-Jassir","year":"2021","journal-title":"BMJ Open"},{"key":"B105","unstructured":"Initial data from the Heart-2 clinical trial of VERVE-102\n          \n          \n          2025"},{"key":"B106","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.bbi.2023.11.008","article-title":"PCSK9 ablation attenuates A\u03b2 pathology, neuroinflammation and cognitive dysfunctions in 5XFAD mice","volume":"115","author":"Vilella","year":"2024","journal-title":"Brain Behav. Immun."},{"key":"B107","doi-asserted-by":"publisher","first-page":"100497","DOI":"10.1016\/j.jlr.2024.100497","article-title":"VXX-401, a novel anti-PCSK9 vaccine, reduces LDL-C in cynomolgus monkeys","volume":"65","author":"Vroom","year":"2024","journal-title":"J. Lipid Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1038\/s41591-026-04254-4","article-title":"In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial","volume":"32","author":"Wan","year":"2026","journal-title":"Nat. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13046-022-02477-0","article-title":"PCSK9 promotes the progression and metastasis of colon cancer cells through regulation of EMT and PI3K\/AKT signaling in tumor cells and phenotypic polarization of macrophages","volume":"41","author":"Wang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e032031","DOI":"10.1161\/jaha.123.032031","article-title":"Harnessing RNA interference for cholesterol lowering: the bench-to-bedside story of inclisiran","volume":"13","author":"Wilkinson","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"B112","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ana.25642","article-title":"Lipid lowering and alzheimer disease risk: a mendelian randomization study","volume":"87","author":"Williams","year":"2020","journal-title":"Ann. Neurol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.3892\/etm.2017.4218","article-title":"PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways","volume":"13","author":"Xu","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"B114","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.tcm.2025.07.002","article-title":"Pushing the limits of LDL cholesterol: emerging paradigms in cardiovascular risk reduction","volume":"35","author":"Yaghoubi","year":"2025","journal-title":"Trends Cardiovasc Med."},{"key":"B115","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s1040-8428(00)00134-7","article-title":"Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy","volume":"38","author":"Yang","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"106916","DOI":"10.1016\/j.isci.2023.106916","article-title":"Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer","volume":"26","author":"Yang","year":"2023","journal-title":"iScience"},{"key":"B117","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s13238-021-00821-2","article-title":"Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling","volume":"12","author":"Yuan","year":"2021","journal-title":"Protein Cell"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00228-021-03149-2","article-title":"A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9","volume":"77","author":"Zeitlinger","year":"2021","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"107340","DOI":"10.1016\/j.phrs.2024.107340","article-title":"Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab","volume":"207","author":"Zhang","year":"2024","journal-title":"Pharmacol. Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamadermatol.2022.6051","article-title":"Association of lipid-lowering drugs with risk of psoriasis: a mendelian randomization study","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3233\/jad-160411","article-title":"Increased PCSK9 cerebrospinal fluid concentrations in alzheimer's disease","volume":"55","author":"Zimetti","year":"2017","journal-title":"J. Alzheimers Dis."}],"updated-by":[{"DOI":"10.3389\/fphar.2026.1964681","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1800502\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:10:39Z","timestamp":1787047839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1800502\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":121,"alternative-id":["10.3389\/fphar.2026.1800502"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1800502","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"1800502"}}